Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Gets Price Target Bump from JPMorgan Chase & Co.

Vertex Pharmaceuticals (NASDAQ:VRTX) had its target price hoisted by JPMorgan Chase & Co. from $560.00 to $570.00 in a note issued to investors on Tuesday, Benzinga reports. The firm currently has an “overweight” rating on the pharmaceutical company’s stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 5.94% from the stock’s previous close.

A number of other analysts have also commented on VRTX. Leerink Partners initiated coverage on shares of Vertex Pharmaceuticals in a report on Monday, September 21st. They set an “outperform” rating and a $594.00 target price for the company. The Goldman Sachs Group increased their price target on Vertex Pharmaceuticals from $654.00 to $725.00 and gave the company a “buy” rating in a research note on Tuesday. Sanford C. Bernstein upgraded Vertex Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, July 29th. Cantor Fitzgerald lifted their price objective on Vertex Pharmaceuticals from $595.00 to $619.00 and gave the stock an “overweight” rating in a research note on Tuesday. Finally, Weiss Ratings raised Vertex Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, October 16th. One analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $596.11.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ VRTX traded down $15.13 during mid-day trading on Tuesday, hitting $538.02. The company’s stock had a trading volume of 1,291,470 shares, compared to its average volume of 1,388,738. The stock has a market cap of $136.55 billion, a price-to-earnings ratio of 31.28, a price-to-earnings-growth ratio of 2.54 and a beta of 0.28. Vertex Pharmaceuticals has a one year low of $403.16 and a one year high of $568.67. The company’s fifty day simple moving average is $523.32 and its 200-day simple moving average is $479.96.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.06). Vertex Pharmaceuticals had a return on equity of 23.09% and a net margin of 35.00%. The business had revenue of $3.44 billion for the quarter, compared to the consensus estimate of $3.42 billion. During the same period last year, the firm earned $4.80 earnings per share. The company’s quarterly revenue was up 11.8% on a year-over-year basis. On average, sell-side analysts predict that Vertex Pharmaceuticals will post 16.74 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Guidance Capital Inc. lifted its holdings in shares of Vertex Pharmaceuticals by 0.9% during the 3rd quarter. Guidance Capital Inc. now owns 2,230 shares of the pharmaceutical company’s stock valued at $1,234,000 after purchasing an additional 19 shares in the last quarter. Bangor Savings Bank grew its position in shares of Vertex Pharmaceuticals by 0.4% in the 2nd quarter. Bangor Savings Bank now owns 4,470 shares of the pharmaceutical company’s stock valued at $2,220,000 after purchasing an additional 20 shares during the period. Trust Point Inc. increased its stake in Vertex Pharmaceuticals by 2.7% during the 2nd quarter. Trust Point Inc. now owns 793 shares of the pharmaceutical company’s stock worth $394,000 after purchasing an additional 21 shares in the last quarter. Integrated Advisors Network LLC increased its stake in Vertex Pharmaceuticals by 1.4% during the 3rd quarter. Integrated Advisors Network LLC now owns 1,625 shares of the pharmaceutical company’s stock worth $850,000 after purchasing an additional 22 shares in the last quarter. Finally, Glenview Trust Co raised its holdings in Vertex Pharmaceuticals by 0.3% during the 3rd quarter. Glenview Trust Co now owns 6,773 shares of the pharmaceutical company’s stock worth $3,541,000 after buying an additional 22 shares during the period. 90.96% of the stock is currently owned by institutional investors.

Trending Headlines about Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Revenue and product growth exceeded expectations. Third-quarter revenue rose 11.8% year over year to $3.44 billion, topping the $3.42 billion consensus estimate. Cystic fibrosis sales remained strong as Alyftrek gains share from Trikafta, while newer products CASGEVY and JOURNAVX continued to ramp. Vertex Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Vertex raised its full-year 2026 sales outlook to $13.2 billion-$13.3 billion, reflecting continued commercial momentum and an increasingly diversified product portfolio. Vertex Raises 2026 Earnings Guidance
• Positive Sentiment: Analysts largely became more constructive. Goldman Sachs raised its target to $725 and kept a Buy rating; Scotiabank, UBS, Wells Fargo, RBC, Cantor Fitzgerald, TD Cowen and Stifel also increased targets, with ratings ranging from Hold to Buy. The revisions indicate Wall Street sees additional upside from new launches and pipeline expansion.
• Positive Sentiment: Longer-term growth opportunities are expanding. Management is building additional commercial pillars in nephrology and rare endocrinology, including assets gained through the Crinetics acquisition. Vertex: Three Key Takeaways for Long-Term Investors
• Neutral Sentiment: Morgan Stanley lowered its target modestly to $660 but maintained an Overweight rating, suggesting confidence remains intact despite more cautious assumptions.
• Negative Sentiment: Quarterly profitability missed expectations. Adjusted EPS was $4.76, below estimates of approximately $4.82-$4.92 and down from $4.80 a year earlier. Spending on new launches and the Crinetics transaction limited earnings growth despite higher sales. Vertex Misses Q3 Earnings Estimates
• Negative Sentiment: The new revenue range broadly aligns with consensus rather than materially exceeding it, leaving investors focused on whether pipeline investments can translate into stronger future earnings.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.